# LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dulaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute pancreatitis**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	159,923	125,129	187	1.49
Merative CCAE	11,162	9,150	16	1.75
Merative MDCD	2,549	1,456	10	6.87
Merative MDCR	1,127	747	<5	<6.69
Optum Clinformatics	12,066	8,213	29	3.53
Optum EHR	13,963	6,975	18	2.58
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)